Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study
Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study
复制标题
68Ga-DOTATATE PET/CT 和 18F-FDG PET/CT 在定位异位促肾上腺皮质激素分泌肿瘤中的头对头比较：一项前瞻性研究
DOI：
10.1007/s00259-021-05370-8
复制
发表时间：
2021-06-19
影响因子：
9.1
通讯作者：
Zhu, Zhaohui
中科院分区：
文献类型：
--
作者：
Liu, Qingxing;Zang, Jie;Zhu, Zhaohui
目的定位异位促肾上腺皮质激素分泌（EAS）的来源具有挑战性。本研究比较Ga-68-DOTATATE PET/CT和F-18-FDG PET/CT对EAS肿瘤的诊断价值。方法对36例疑似EAS患者在4周内进行了Ga-68-DOTATATE PET/CT和F-18-FDG PET/CT检查，并进行比较。23例接受手术切除或活检。SSTR 2和Ki-67的免疫组化染色分别与Ga-68-DOTATATE摄取和F-18-FDG摄取相关。在20例组织学证实的EAS肿瘤患者中，Ga-68-DOTATATE PET/CT正确识别了15例（75.0%）肿瘤，SUVmax范围为1.4至20.7（6.7 +/- 5.5）。F-18-FDG PET/CT正确识别了12例（60.0%）患者的肿瘤，SUVmax范围为1.8至10.0（4.0 +/- 2.1）。此外，Ga-68-DOTATATE PET/CT在6例F-18-FDG摄取阴性的患者中揭示了EAS的来源，并且F-18-FDG PET/CT在3例Ga-68-DOTATATE摄取阴性的患者中揭示了EAS的来源，结果Ga-68-DOTATATE PET/CT和F-18-FDG PET/CT联合诊断EAS肿瘤18例（90%）。FDGPET/CT在EAS的定位和鉴别诊断方面具有互补性。Ga-68-DOTATATE PET/CT联合F-18-FDG PET/CT的检出率高于单独使用。注册表的URL
Purpose Localizing the source of ectopic adrenocorticotropic hormone secretion (EAS) is challenging. This study compared the diagnostic value of Ga-68-DOTATATE PET/CT and F-18-FDG PET/CT in tumors with EAS. Methods Thirty-six patients with a suspicion of EAS were enrolled to undergo both Ga-68-DOTATATE PET/CT and F-18-FDG PET/CT within 4 weeks for comparison. Twenty-three underwent surgical resection or biopsy. Immunohistochemical staining for SSTR2 and Ki-67 was performed to correlate with Ga-68-DOTATATE uptake and F-18-FDG uptake, respectively.Results EAS tumors were observed in 20/23 patients. Among the 20 patients with histologically proven EAS tumors, Ga-68-DOTATATE PET/CT correctly identified the tumor in 15 (75.0%), with an SUVmax ranging from 1.4 to 20.7 (6.7 +/- 5.5). F-18-FDG PET/CT correctly identified the tumor in 12 (60.0%) patients, with an SUVmax ranging from 1.8 to 10.0 (4.0 +/- 2.1). Moreover, Ga-68-DOTATATE PET/CT unmasked the sources of EAS in 6 patients with negative F-18-FDG uptake, and F-18-FDG PET/CT unmasked the sources in 3 patients with negative Ga-68-DOTATATE uptake, resulting in EAS tumors being identified in 18 (90%) patients by combining Ga-68-DOTATATE PET/CT and F-18-FDG PET/CT.Conclusions Ga-68-DOTATATE PET/CT and F-18-FDG PET/CT are complementary in localizing and discriminating the source of EAS. Ga-68-DOTATATE PET/CT combined with F-18-FDG PET/CT had higher detection rate than each alone. URL of registry